Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The study drug cabozantinib works by inhibiting several different proteins which are believed
to be involved in breast cancer tumor growth, its ability to spread, and its ability to form
new blood vessels. This drug has been used in other research studies and information from
those other research studies suggests that this drug may help to prevent cancer growth.
The single agent portion of this study is now closed to accrual. This research study is now
examining the efficacy of cabozantinib in combination with fulvestrant for treatment of
hormone-receptor-positive breast cancer that has spread to bone.